Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

HHS Secretary Azar explains why companies have not voluntarily lowered prices as yet, despite President Trump’s recent comments. He also discussed using regulations to prohibit rebates.